RxDoctor Payments Data

Jeremy Eades

Family · Miami Beach, FLNPI 1154998292

Payments from drug & device makers

$1,261in general payments, 2019–2025

Across 19 payments — averaging $66.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$406
  • Johnson & Johnson$145
  • Myriad Genetic Laboratories, Inc.$136
  • Viiv Healthcare Company$125
  • Neurocrine Biosciences, Inc.$116
  • Neurelis, Inc.$108
  • plus $226 from 4 others

What the payments were for

  • Food & beverage$1,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,261 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$14,163
Medicare patients
71
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron27$14,821
Estradiol12$855
Albuterol Sulfate HfaAlbuterol Sulfate28$846
Levothyroxine Sodium26$743
Atorvastatin Calcium47$671
Tamsulosin Hcl48$640
Ventolin HfaAlbuterol Sulfate15$632
Omeprazole24$408
Rosuvastatin Calcium16$368
Gabapentin19$362
Lisinopril36$341
Amlodipine Besylate42$307
Losartan Potassium21$226
Metoprolol Succinate18$216
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$40$14,82127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →